-Advertisement-
-Advertisement-
FDA Alerts
Hematology
Trending Topics
FDA approves pralsetinib for RET-altered thyroid cancers
Posted on
The U.S. Food and Drug Administration approved pralsetinib (Gavreto; Blueprint Medicines Corporation) for advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), according to a press release. The approval is for adult and pediatric patients ≥12 years old.
Read the full press release here.
SOURCE: U.S. Food and Drug Administration
-Advertisement-
-Advertisement-
Contact
© 2025 Med Journal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved